NLNK Lumos Pharma Inc.

NewLink Genetics to Host Its First Quarter 2019 Conference Call on May 8, 2019

NewLink Genetics to Host Its First Quarter 2019 Conference Call on May 8, 2019

AMES, Iowa, April 24, 2019 (GLOBE NEWSWIRE) -- (NASDAQ:NLNK) today announced it will host its first quarter 2019 conference call and webcast at 4:30 PM ET on Wednesday, May 8, 2019, to discuss its first quarter financial results and provide an update of its clinical development activities. There will also be a question and answer session following the prepared remarks.

Investors and the general public are invited to listen to a live audio webcast of the conference call, which can be accessed five minutes prior to the start of the call by dialing (855) 469-0612 (U.S.) or (484) 756-4268 (international). The conference call will be webcast live and a link can be accessed through the NewLink Genetics website at . A replay of the call will be available for two weeks from the date of the call and can be accessed by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (international) and using the passcode: 8457627.

About NewLink Genetics Corporation

NewLink Genetics is a clinical stage biopharmaceutical company focusing on developing novel oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' IDO pathway inhibitors, indoximod and its prodrug, NLG802, are immuno-oncology drug candidates designed to harness multiple components of the immune system to combat cancer. NewLink Genetics’ drug candidate, NLG207, is a nanoparticle formulation of the topoisomerase 1 inhibitor, camptothecin, under development to combat refractory malignancies. For more information, please visit and follow us on Twitter .

Investor & Media Contact:

Lisa Miller

Director of Investor Relations

NewLink Genetics

515-598-2555

Source: NewLink Genetics Corporation

EN
24/04/2019

Underlying

NLNKLumos Pharma Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lumos Pharma Inc.

 PRESS RELEASE
Free
NLNK Lumos Pharma I...

Lumos Pharma Appoints Joseph S. McCracken, DVM, MS to Board of Directo...

Lumos Pharma Appoints Joseph S. McCracken, DVM, MS to Board of Directors Rick Hawkins, CEO, appointed Chairman of the Board AUSTIN, Texas, March 30, 2020 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, has announced the appointment of Joseph S. McCracken, DVM, MS to the company's Board of Directors, effective March 23, 2020. Dr. McCracken has extensive experience in the pharmaceutical and biotechnology industry, with prominent roles in business development, commercial development, and positions as board member for s...

March 30, 2020 1 EN
 PRESS RELEASE
Free
NLNK Lumos Pharma I...

NewLink Genetics Stockholders Approve Merger with Lumos Pharma

NewLink Genetics Stockholders Approve Merger with Lumos Pharma - Combined company, Lumos Pharma, Inc., to trade on Nasdaq under the stock symbol “LUMO” - Phase 2b trial expected to be initiated mid-2020 evaluating oral therapeutic candidate LUM-201 (ibutamoren) in Pediatric Growth Hormone Deficiency (PGHD) - Projected combined cash on March 31, 2020 in excess of $80 million expected to be sufficient to fund company through Phase 2b trial in PGHD data read-out AUSTIN, Texas and AMES, Iowa, March 18, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (Lumos Pharma) and NewLink Genetics Corpora...

March 18, 2020 1 EN
 PRESS RELEASE
Free
NLNK Lumos Pharma I...

NewLink Genetics Reports Fourth Quarter and Full Year 2019 Financial R...

NewLink Genetics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update Special Meeting of Stockholders set for March 17, 2020 for vote on proposed merger of NewLink Genetics and Lumos Pharma AMES, Iowa, Feb. 28, 2020 (GLOBE NEWSWIRE) -- (NASDAQ:NLNK) today announced financial results for the fourth quarter and full year ended December 31, 2019, and provided an update on corporate activities. “We continue to focus our work toward the anticipated completion of our proposed merger with Lumos Pharma,” stated Carl Langren, Chief Financial Officer, and me...

February 28, 2020 1 EN
Free Trial
NLNK Lumos Pharma I...

NEWLINK GENETICS CORP. suffers a double requalification, which weighs ...

The independent financial analyst theScreener just downgraded the general evaluation of NEWLINK GENETICS CORP. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title loses a star(s) and now shows 0 out of 4 stars. Its market behaviour is also negatively reassessed and may be considered as risky. theScreener believes that this double requalification keeps the title under pressure and justifies an overall rating downgrade to Negative. As of the analysis date Ja...

NLNK LUMOS PHARMA INC.
01/25/20 January 25, 2020 6 EN
 PRESS RELEASE
Free
NLNK Lumos Pharma I...

NewLink Genetics Announces Exclusive Worldwide License Agreement with ...

NewLink Genetics Announces Exclusive Worldwide License Agreement with Ellipses Pharma for Development of and Rights to Commercialization of NLG207 AMES, Iowa, Dec. 23, 2019 (GLOBE NEWSWIRE) -- (NASDAQ:NLNK) announced today that the company has entered into an exclusive worldwide license agreement with Ellipses Pharma Limited (Ellipses) for the development of and rights to commercialize NLG207 (formerly CRLX101), a nanoparticle formulation of the topoisomerase 1 inhibitor camptothecin. This license agreement signed by NewLink Genetics and Ellipses is effective as of December 17, 2019. Und...

December 23, 2019 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch